Therapy of chronic lymphocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 1, 2010, Pages 85-96

  Hallek, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

allogeneic stem cell transplantation; antibody; CLL; first line second line; fitness; purin analogue; rituximab; therapy

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; ALKYLATING AGENT; ANTIBIOTIC AGENT; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; LENALIDOMIDE; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; OBLIMERSEN; OFATUMUMAB; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOPENIA; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GERIATRIC PATIENT; GOLD STANDARD; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECONDARY ACUTE LEUKEMIA; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TRANSPLANTATION, HOMOLOGOUS;

EID: 77956627474     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.12.002     Document Type: Review

References (65)

1. CLL trialists' collaborative group Chemotherapeutic options in chronic lymphocytic leukemia J Natl Cancer Inst 91 1999 861 868
2. S. O'Brien, H. Kantarjian, and M.J. Keating Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinaemia Ann Oncol 7 Suppl. 6 1996 S27 S33
3. B. Cheson The purine analogs - a therapeutic beauty contest J Clin Oncol 10 1992 352 355
4. E.J. Anaissie, D.P. Kontoyiannis, and S. O'Brien Infections in patients with chronic lymphocytic leukemia treated with fludarabine Ann Intern Med 129 7 1998 559 566
5. W. Plunkett, V. Gandhi, and P. Huang Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies Semin Oncol 20 5 Suppl. 7 1993 2 12
6. K.R. Rai, B.L. Peterson, and F.R. Appelbaum Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 24 2000 1750 1757
7. M. Steurer, G. Pall, and S. Richards Purine antagonists for chronic lymphocytic leukaemia Cochrane Database Syst Rev 3 2006 CD004270
8. S. Johnson, A.G. Smith, and H. Loffler Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL [see comments] Lancet 347 9013 1996 1432 1438
9. M. Leporrier, S. Chevret, and B. Cazin Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients Blood 98 8 2001 2319 2325
10. T. Robak, J.Z. Blonski, and M. Kasznicki Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial Blood 96 8 2000 2723 2729
11. W.U. Knauf, T. Lissichkov, and A. Aldaoud Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia J Clin Oncol 27 26 2009 Sep 10 4378 4384
12. D. Huhn, C. von Schilling, and M. Wilhelm Rituximab therapy of patients with B-cell chronic lymphocytic leukemia Blood 98 5 2001 1326 1331
13. S. O'Brien, H. Kantarijan, and D. Thomas Rituximab dose-escalation trial in chronic lymphocytic leukaemia J Clin Oncol 19 2001 2165 2170
14. J. Byrd, T. Murphy, and R. Howard Rituximab using a thrice-weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity J Clin Oncol 19 2001 2153 2164
15. A. Österborg, M.J. Dyer, and D. Bunjes Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia J Clin Oncol 15 4 1997 1567 1574
16. K.R. Rai, C.E. Freter, and R.J. Mercier Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine J Clin Oncol 20 18 2002 Sep 15 3891 3897
17. M.J. Keating, I. Flinn, and V. Jain Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 99 10 2002 May 15 3554 3561
18. S. Stilgenbauer, and H. Dohner Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy N Engl J Med 347 6 2002 Aug 8 452 453
19. G. Lozanski, N.A. Heerema, and I.W. Flinn Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Blood 103 9 2004 May 1 3278 3281
20. P. Hillmen, A.B. Skotnicki, and T. Robak Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 35 2007 Dec 10 5616 5623
21. B. Bellosillo, N. Villamor, and D. Colomer In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia Blood 94 8 1999 2836 2843
22. M. Hallek, and B.F. Eichhorst Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia Hematol J 5 Suppl. 1 2004 S20 S30
23. B.F. Eichhorst, R. Busch, and G. Hopfinger Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Blood 107 2006 885 891
24. I.W. Flinn, D.S. Neuberg, and M.R. Grever Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997 J Clin Oncol 25 7 2007 Mar 1 793 798
25. D. Catovsky, S. Richards, and E. Matutes Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 9583 2007 Jul 21 230 239
26. Stilgenbauer S, Eichhorst BF, Busch R, et-al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC) - comprehensive analysis of the CLL4 trial of the GCLLSG. ASH annual meeting abstracts. 2008 November 16, 2008;112(11):2089.
27. F. Bosch, A. Ferrer, and A. Lopez-Guillermo Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia Br J Haematol 119 4 2002 Dec 976 984
28. M. Montillo, A. Tedeschi, and S. O'Brien Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia Cancer 97 1 2003 Jan 1 114 120 (Pubitemid 36033870)
29. T. Robak, J.Z. Blonski, and J. Gora-Tybor Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2) Blood 108 2 2006 Jul 15 473 479
30. N. di Gaetano, Y. Xiao, and E. Erba Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone Br J Haematol 114 4 2001 800 809
31. H. Schulz, S.H. Klein, and U. Rehwald Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia Blood 100 9 2002 3115 3120
32. J.C. Byrd, B.L. Peterson, and V.A. Morrison Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood 101 1 2003 Jan 1 6 14
33. J.C. Byrd, K. Rai, and B.L. Peterson Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood 105 1 2005 Jan 1 49 53
34. C.S. Tam, S. O'Brien, and W. Wierda Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 4 2008 Aug 15 975 980
35. Hallek M, Fingerle-Rowson G, Fink A-M, et-al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH annual meeting abstracts. 2008 November 16, 2008;112(11):325.
36. Robak T, Moiseev SI, Dmoszynska A, et-al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial. ASH annual meeting abstracts. 2008 November 16, 2008;112(11):lba-1.
37. K.A. Foon, M. Boyiadzis, and S.R. Land Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia J Clin Oncol 27 4 2009 Feb 1 498 503
38. M. Hallek, B.D. Cheson, and D. Catovsky Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 12 2008 Jun 15 5446 5456
39. Bosch F, Abrisqueta P, Villamor N, et-al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) is a highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. ASH annual meeting abstracts. 2008;112: 2097.
40. Reynolds C, Di Bella N, Lyons RM, et-al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. ASH annual meeting abstracts. 2008;112:327.
41. Fischer K, Stilgenbauer S, Schweighofer CD, et-al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG). ASH annual meeting abstracts. 2008 November 16, 2008;112(11):330.
42. B. Kennedy, A. Rawstron, and C. Carter Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia Blood 99 6 2002 2245 2247
43. T. Elter, P. Borchmann, and H. Schulz Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial J Clin Oncol 23 28 2005 Oct 1 7024 7031
44. Elter T, James R, Stilgenbauer S, et-al. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab in patients with relapsed/refractory CLL: interim analysis of the CLL2L trial of the German CLL study group. ASH annual meeting abstracts. 2008 November 16, 2008;112(11):3170.
45. S. Lepretre, T. Aurran, and B. Mahé Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C), and mabcampath (CAM) (FCCAM) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/WM) and the "Groupe Ouest-Est d'Etudes des Leucémies Aigües et autres Maladies du Sang" (GOELAMS): CLL2007FMP (for medically fit patients) (abstr. 7.5) Haematologica 94 s3 2009 S67
46. S. Faderl, D.A. Thomas, and S. O'Brien Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies Blood 101 9 2003 May 1 3413 3415
47. J.C. Byrd, S. O'Brien, and I.W. Flinn Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia Clin Cancer Res 13 15 Pt 1 2007 Aug 1 4448 4455 (Pubitemid 47219713)
48. Byrd JC, Castro J, O'Brien S, et-al. Comparison of results from a phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. ASH annual meeting abstracts. 2006 November 16, 2006;108(11):32.
49. W. Wierda, S. O'Brien, and S. Wen Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 18 2005 Jun 20 4070 4078 (Pubitemid 46211312)
50. S. O'Brien, J.O. Moore, and T.E. Boyd Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia J Clin Oncol 25 9 2007 Mar 20 1114 1120
51. A. Chanan-Khan, K.C. Miller, and L. Musial Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study J Clin Oncol 24 34 2006 Dec 1 5343 5349
52. J.C. Byrd, T.S. Lin, and J.T. Dalton Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood 109 2 2007 Jan 15 399 404
53. C.D. Schweighofer, M. Ritgen, and B.F. Eichhorst Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG) Br J Haematol 144 1 2009 Jan 95 98
54. P. Moreton, B. Kennedy, and G. Lucas Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival J Clin Oncol 23 2005 Feb 28 2971 2979
55. M. Montillo, A.M. Cafro, and A. Tedeschi Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine Haematologica 87 7 2002 695 700 discussion
56. S.M. O'Brien, H.M. Kantarjian, and D.A. Thomas Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia Cancer 98 12 2003 Dec 15 2657 2663
57. S.T. Abrams, T. Lakum, and K. Lin B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII Blood 109 3 2007 Feb 1 1193 1201
58. C.M. Wendtner, M. Ritgen, and C.D. Schweighofer Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) Leukemia 18 6 2004 Jun 1093 1101
59. Boettcher S, Fischer K, Stilgenbauer S, et-al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. ASH annual meeting abstracts. 2008 November 16, 2008;112(11):326.
60. A.C. Rawstron, N. Villamor, and M. Ritgen International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia Leukemia 21 5 2007 May 956 964
61. M. Extermann, J. Overcash, and G.H. Lyman Comorbidity and functional status are independent in older patients J Clin Oncol 16 4 1998 1582 1587
62. S. Stilgenbauer, T. Zenz, and D. Winkler Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German chronic lymphocytic leukemia study group J Clin Oncol 2009 Jul 13
63. P. Dreger, P. Corradini, and E. Kimby Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus Leukemia 21 1 2007 Jan 12 17
64. B.F. Eichhorst, R. Busch, and S. Stilgenbauer First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood 114 16 2009 Oct 15 3382 3391
65. Knauf WU, Lissichkov T, Aldaoud A, et-al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. ASH annual meeting abstracts. 2007 November 16, 2007;110(11):2043.